University of Ioannina
Ανοσοϊστοχημική μελέτη της αγγειογένεσης και της λεμφαγγειογένεσης στα καρκινώματα των πνευμόνων: συσχέτιση με τις κλινικές παραμέτρους και την πρόγνωση
Abstract
dc:descriptionTumor angiogenesis (formation of new vasculature) being currently a special point of interest in several experimental studies, constitutes a major event in tumor formation and metastatic spread being triggered and controlled by neoplastic cells. Vascular Endothelial Growth Factor (VEGF) is a secretory glycoprotein acting as a specific endothelial mitogen and facilitating angiogenesis in actively developing cancer cell areas. It comprises one of the most important and specific angiogenetic factors and plays a pivotal role in tumor formation being mediated through VEGF-R1-Flt1 and VEGF-R2-Flk1. Lymphangiogenesis (formation of new lymphatic vessels) is considered to be of importance in the metastatic spread of cancer cells as lymphatic vessels constitute the initial route of spread in this procedure. CD105 (Endoglin) is expressed on the cell surface as a 180 kDa homodimeric transmembrane protein and is believed to constitute a role in lymphangiogenenesis but its expression in lymphatic vessels is less clear. The association of angiogenesis with lymphangiogenesis and the metastatic spread of cancer cells in lung carcinomas still remains vague and has not been thoroughly studied. The present study aims to evaluate angiogenesis and lymphangiogenesis in non-small cell lung carcinomas (NSCLC) and small cell lung carcinomas (SCLC) and to detect their possible association by means of immunohistochemistry. We emphasized in investigating any prognostic impact of these procedures on patient outcome by associating the immunohistochemical findings with clinical and demographical data available. A retrospective study was undertaken in 146 surgical lung specimens, 96 being NSCLC and 50 SCLC. Immunohistochemical staining for VEGF, VEGF-R1-Flt1, VEGF-R2-Flk1 and lymphangiogenetic factor CD105 was performed. Expression of VEGF, VEGF-R1-Flt1 and VEGF-R2-Flk1 were assessed, intratumoral lymphatic microvessel density (ILMVD) was calculated and lymphatic invasion was detected (when existed). The patients’ medical records were thoroughly reviewed and clinical parameters were correlated with the immunohistochemical results as mentioned. VEGF was higher expressed in NSCLC than in SCLC and its two receptors VEGF-R1-Flt1 and VEGF-R2-Flk1 presented the same behavioural pattern. CD105 was highly expressed in both histologic subtypes of lung carcinomas, mainly in SCLC where VEGF expression was diminished. In all specimens, VEGF expression was only correlated with VEGF-R1-Flt1 expression and not with VEGF-R2-Flk1. Moreover, VEGF did not associate with the patients’ demographical data (age, sex) and clinical parameters (clinical stage, presence of metastases, survival). VEGF-R1-Flt1 receptor was only associated in NSCLC with the clinical stage while VEGF-R2-Flk1 receptor was associated in NSCLC with both the clinical stage and the presence of metastases while in SCLC was only associated with the stage of the disease. In NSCLC, CD105 expression (by means of ILMVD assessment) was associated with the patients’ age, the clinical stage and metastases in target organs (adrenal glands, liver, brain, bones). It maintained the same behavioral pattern in SCLC differing only in the lack of association with survival. The present observation could be attributed to the use of chemotherapy and radiation according to the individuality of each clinical case and not on a massive basis, thus constituting a fact not being thoroughly examined in the present study as it does not comprise part of its aims. Although lymphatic invasion was detected in both NSCLC and SCLC it was associated with clinical parameters only in NSCLC. Our findings ascertain the fact that angiogenesis is higher expressed in NSCLC than in SCLC whereas lymphangiogenesis is expressed in both histological subgroups, mainly in SCLC. The inability of VEGF correlation with the clinical parameters proves that this angiogenetic factor is devoid of prognostic value in lung neoplasms. On the contrary, CD105 expression by means of assessing ILMVD and lymphatic invasion was strongly associated with clinical staging and metastasis, thus demonstrating its validity as a marker of lymphangiogenesis and constituting a strong possibility for its future utilization as a prognostic factor for patient outcome in lung neoplasms.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Hardavella, Georgia
- Χαρδαβέλλα, Γεωργία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21935